Global UAV Announces Share Consolidation
The proposed Nexus Peptide Sciences combination remains subject to CSE approval, with trading halted pending completion of the exchange review.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Global UAV Technologies (YRLLF) plans a share consolidation at a ratio of 1.324206 existing shares for one share, effective October 13, 2026.
Issued and outstanding shares will move from 43,698,801 to 33,000,002, subject to rounding adjustments. Fractional shares will be rounded up. The consolidation is intended to satisfy a requirement for no more than 33,000,000 shares immediately before closing the proposed business combination with Nexus Peptide Sciences, under an existing amalgamation agreement.
The transaction remains subject to Canadian Securities Exchange approval and other closing conditions. Trading remains halted pending completion of the exchange's review. Outstanding convertible securities' exercise or conversion prices and issuable share counts will be proportionately adjusted.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Amalgamation agreement with Nexus Peptide Sciences establishes terms for the proposed business combination.
Negative
- Moderate pointTrading remains halted pending completion of the CSE review of the proposed transaction.
- Minor point. Forward-looking: it has not happened yet and may not happen.Proposed business combination remains subject to CSE approval and other closing conditions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2026) - Global UAV Technologies Ltd. (CSE: UAV.X) (OTC Pink: YRLLF) (FSE: YAB) (the "Company") is pleased to announce that it intends to consolidate the common shares of the Company (each, a "Share") on the basis of one (1) post-consolidated Share for each one and three hundred twenty-four thousand two hundred six millionths (1.324206) pre-consolidated Shares issued and outstanding (the "Consolidation").
The Consolidation will become effective at the opening of the market on October 13, 2026. The symbol "UAV.X" will remain the same. The new CUSIP number will be 379433402 and the new ISIN number will be CA3794334027 for the post-Consolidation Shares. Currently, a total of 43,698,801 Shares are issued and outstanding. Accordingly, upon the Consolidation becoming effective, a total of 33,000,002 Shares, subject to adjustments for rounding, will be issued and outstanding. Any fractional Shares resulting from the exchange will be rounded up to the nearest whole Share. The exercise or conversion price, as well as the number of Shares issuable with respect to any of the Company's outstanding convertible securities will be proportionately adjusted in connection with the Consolidation. There is no maximum number of authorized Shares.
As previously announced, the Company entered into an amalgamation agreement with Nexus Peptide Sciences Inc. pursuant to which the Company proposes to complete a business combination transaction constituting a Fundamental Change under the policies of the Canadian Securities Exchange ("CSE"). The Consolidation is being completed to satisfy the requirement that the Company have no more than 33,000,000 Shares issued and outstanding immediately prior to closing. Completion of the transaction remains subject to a number of conditions, including CSE approval and the satisfaction of other customary closing conditions. There can be no assurance that the transaction will be completed as proposed or at all.
Trading in the Company's securities remains halted in accordance with the policies of the CSE pending completion of the review process in respect of the proposed transaction.
Endeavor Trust Corporation has confirmed that all Shares held by registered shareholders as of the record date on October 13, 2026, will be processed.
On Behalf of the Board of Directors
"Ron Schmitz"
Ron Schmitz
Director, President and CEO
Telephone: (604) 685-7450
Forward-Looking Statements
This news release includes certain "forward-looking statements" under applicable Canadian securities legislation that are not historical facts. Forward-looking statements involve risks, uncertainties, and other factors that could cause actual results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements in this news release include statements regarding timing and dates of all matters with respect to the Consolidation, the receipt of approval from the CSE for the Consolidation and the expected timing of commencement of trading, the completion of the proposed business combination transaction with Nexus Peptide Sciences Inc., the satisfaction of conditions precedent to such transaction, and the anticipated timing thereof. Such forward-looking statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements including, with respect to the Consolidation, the receipt of approval from the CSE for the Consolidation and the expected timing of commencement of trading, the failure to satisfy conditions to closing of the proposed transaction with Nexus, the failure to obtain regulatory approvals, including approval of the CSE, and the risk that the proposed transaction may not be completed on the terms anticipated or at all, as stated in this news release and those additional risks set out in the Company's public documents filed on SEDAR+ at www.sedarplus.ca. Although the Company believes that the assumptions and factors used in preparing the forward-looking statements are reasonable, undue reliance should not be placed on these statements, which only apply as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Except where required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/317794
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.